Overview

* Day One Q2 2025 OJEMDA rev up 310% yr/yr to $33.6 mln

* Company reports Q2 net loss of $30.3 mln

* Ended Q2 with $453.1 mln in cash, cash equivalents, and investments

Outlook

* Company expects full-year 2025 OJEMDA revenue of $140 mln to $150 mln

Result Drivers

* OJEMDA SALES - OJEMDA net product revenue increased 310% yr/yr to $33.6 mln, driven by higher prescription volumes

* PRESCRIPTION GROWTH - OJEMDA prescriptions exceeded 1,000 in Q2 2025, a 15% increase from Q1 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS -$0.29

Q2 Net -$30.32

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Day One Biopharmaceuticals Inc ( DAWN ) is $25.00, about 73.1% above its August 4 closing price of $6.74

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)